Noteworthy is the recent results from a phase 1/2 vaccination study combining PD-L1 and indoleamine-2,3-dioxygenase (IDO)-derived peptides in combination with the anti-PD-1 monoclonal antibody nivolumab in patients with malignant melanoma (22). Here, IDO1 is linked to melanoma.